Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

Vanderbilt researchers have identified and characterized inhibitors of an enzyme that synthesizes lipid signaling molecules with roles in energy balance, inflammation and addiction.

A multidisciplinary team from Vanderbilt University Medical Center and Columbia University has demonstrated that injured human donor lungs declined for transplant can be recovered by cross-circulation between the human lung and a xenogeneic host.

Vanderbilt immunologists have discovered that the protein Nur77 is part of a control mechanism that guards against autoimmunity in natural killer T cells.

The IVY Research Network has completed initial studies evaluating the epidemiology of COVID-19 in health care workers and patients.